Now Enrolling: Real-World Registry Study of BRUMVI (Ublituximab-xiiy) in Relapsing Multiple Sclerosis - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Now Enrolling: Real-World Registry Study of BRUMVI (Ublituximab-xiiy) in Relapsing Multiple Sclerosis

Baptist Health Brain & Spine Care is enrolling patients with confirmed multiple sclerosis who are starting BRUMVI to track outcomes, safety, and patient experience over time in a real-world setting.

  • March 4, 2026

  • 2 min

Share

Clinical Scorecard: Now Enrolling: Real-World Registry Study of BRUMVI (Ublituximab-xiiy) in Relapsing Multiple Sclerosis

At a Glance

CategoryDetail
ConditionRelapsing Multiple Sclerosis
Key MechanismsObservational registry to track outcomes, safety, and patient experience with BRUMVI.
Target PopulationPatients with confirmed multiple sclerosis starting BRUMVI.
Care SettingReal-world clinical practice.

Key Highlights

  • Observational registry collecting real-world data on BRUMVI.
  • Focus on outcomes, safety, and patient experience over 192 weeks.
  • Eligibility includes confirmed MS diagnosis and no prior BRUMVI infusions.

Guideline-Based Recommendations

Diagnosis

  • Confirmed diagnosis of multiple sclerosis.

Management

  • Patients should be prescribed BRUMVI and not have received prior infusions.

Monitoring & Follow-up

  • Participants complete health questionnaires and brief assessments.

Risks

  • Exclusion for recent live vaccines and active infections.

Patient & Prescribing Data

Patients with relapsing multiple sclerosis starting BRUMVI.

Registry aims to gather data on the efficacy and safety of BRUMVI in everyday practice.

Clinical Best Practices

  • Continue usual clinical care while participating in the registry.
  • Ensure eligibility criteria are met before referral.

Related Resources & Content

Original Source(s)

Now Enrolling: Real-World Registry Study of BRUMVI (Ublituximab-xiiy) in Relapsing Multiple Sclerosis

  • March 4, 2026

Related Content

Correction: Defining post–colon capsule endoscopy colorectal cancer (pCCECRC)—an International Capsule Endoscopy Research (iCARE) group consensus statement

Adaptive Radiation Boost for Rectal Cancer (ARBOR)

The goal of this clinical trial is to find out if giving extra adaptive radiation therapy after standard chemoradiation treatment is safe and helpful for people with rectal cancer.

  • by

  • September 4, 2026

  • 3 min
Retraction Note: TWIST1 activates cancer stem cell marker genes to promote epithelial‑mesenchymal transition and tumorigenesis in esophageal squamous cell carcinoma